Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance

Oncotarget. 2018 Aug 17;9(64):32403. doi: 10.18632/oncotarget.26020.

Man Kit Siu^#^{1

2}, Wassim Abou-Kheir^#³, Juan Juan Yin^#⁴, Yung-Sheng Chang¹, Ben Barrett⁴, Florent Suau⁴, Orla Casey⁴, Wei-Yu Chen⁵, Lei Fang⁴, Paul Hynes⁴, Yao-Yu Hsieh^{1

6

7}, Yen-Nien Liu^{1

8}, Jiaoti Huang⁹, Kathleen Kelly⁴

¹ Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
² Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
³ Department of Anatomy, Cell Biology and Physiological Sciences Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
⁴ Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁵ Department of Pathology, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁶ Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
⁷ Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁸ Center of Excellence for Cancer Research, Wan Fang Hospital, College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁹ Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.

^# Contributed equally.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.1994.].